HIGHTIDE-B once surged 10% in collaboration with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences on research projects

Zhitong
2025.08.13 08:12

HIGHTIDE-B surged 10% to HKD 3.39 during intraday trading today, with a cumulative increase of 1.67 times this year. HIGHTIDE announced last night that its wholly-owned subsidiary, Shenzhen HIGHTIDE Biotechnology Co., Ltd., is collaborating with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences to assess the treatment potential of the group's core product HTD1801 for diabetes with chronic kidney disease. The two parties will conduct pharmacological and mechanism research on new drugs based on isoquinoline and advance clinical evaluation to expand its clinical applications in the field of diabetes-related kidney diseases. The announcement stated that this cooperation will accelerate the clinical progress of the group's core projects, expand the research and development layout, and further enrich the product pipeline, providing strong support for the company's continuous innovation and long-term development in the treatment of metabolic diseases

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer